Overview

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Status:
Completed

Trial end date:
2012-06-22

Target enrollment:

Participant gender:

Summary

This study is to compare the pharmacokinetics of FK949E low dose tablets and FK949E high dose tablets in non-elderly patients with major depressive disorder. The safety of FK949E in the population was also evaluated.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Quetiapine Fumarate